Yuxing Li, PhD

1985-1989: B.S. - Sichuan University, Chengdu, Sichuan, China (Genetics)

1989-1992: M.S. - Sichuan Industrial Institute of Antibiotics, The State Food and Drug Administration (SFDA), Chengdu, China (Microbiology)

1992-1996: Ph.D. - Iowa State University, Ames, IA (Genetics)

Dr. Yuxing Li obtained her PhD degree from Iowa State University majored in Genetics. After a postdoc training under the supervision of Dr. Susan Carpenter at Iowa State University on lentivirus pathogenesis and persistence, she joined Dr. Richard T. Wyatt’s laboratory in the Vaccine Research Center (VRC), NIAID/NIH as a research fellow.  At VRC, Dr. Li interacted and worked closely with scientists working on HIV structural biology, virology, and immunology, including Peter Kwong, Mark Connors, Mario Roederer, and John Mascola.  During the training at VRC, Dr. Li started to develop an integrated research program focused on HIV vaccine rational design based on HIV envelope glycoprotein structural and immunologic analysis.  In 2010, Dr. Li joined the IAVI Neutralizing Antibody Center at The Scripps Research Institute as an Assistant Professor of Immunology, based in La Jolla, California. In 2014, Dr. Li relocated her laboratory to the Institute for Bioscience and Biotechnology Research (IBBR) in Rockville, Maryland and affiliated with Department of Microbiology and Immunology, University of Maryland School of Medicine.

HIV-1, neutralizing antibody, B cell, Ebola virus, vaccine, immunotherapeutics, structural biology

Steinhardt JJ, Guenaga J, Turner HL, McKee K, Louder MK, O’Dell S, Chiang CI, Lei L, Galkin A, Andrianov AK, Doria-Rose N, Bailer RT, Ward AB, Mascola JR, Li Y. Rational Design of a Trispecific Antibody Targeting the HIV-1 Env with Elevated Anti-viral Activity. Nature Communications.(2018). 9, 877. PMID: 29491415. PMCID: PMC5830440.

Zhao X*, Howell KA*, He S, Brannan JM, Wec AZ, Davidson E, Turner HL, Chiang CI, Lei L, Fels JM, Vu H, Shulenin S, Turonis AN, Kuehne AI, Liu G, Ta M, Wang Y, Sundling C, Xiao Y, Spence JS, Doranz BJ, Holtsberg FW, Ward AB, Chandran K, Dye JM, Qiu X, Li Y#, Aman MJ#. Immunization-elicited Broadly Protective Antibody Reveals Ebolavirus Fusion Loop as a Site of Vulnerability. Cell. (2017). 169, 891-904.e15. (# Co-correspondence author). PMID:28525756.

Wang Y, Sundling C, Wilson R, O'Dell S, Chen Y, Dai K, Phad GE, Zhu J, Xiao Y, Mascola JR, Karlsson Hedestam GB, Wyatt RT, Li Y. (2016). High-Resolution Longitudinal Study of HIV-1 Env Vaccine-Elicited B Cell Responses to the Virus Primary Receptor Binding Site Reveals Affinity Maturation and Clonal Persistence. Journal of Immunology. 196, 3729-43. PMID: 27001953.

Kong L*, Ju B*, Chen Y*, He L*, Ren L*, Liu J*, Hong K, Su B, Wang Z, Ozorowski G, Ji X, Hua Y, Chen Y, Deller MC, Hao Y, Feng Y, Garces F, Wilson R, Dai K, O'Dell S, McKee K, Mascola JR, Ward AB, Wyatt RT, Li Y#, Wilson IA#, Zhu J#, Shao Y#. (2016). Key gp120 Glycans Pose Roadblocks to the Rapid Development of VRC01-Class Antibodies in an HIV-1-Infected Chinese Donor. Immunity, 44, 939-950.  (#, Co-senior authors). PMID: 27067056.

Wu X*, Yang Z-Y*, Li Y*, Hogerkorp C-M, Schief W, Seaman M.S, Zhou T, Schmidt S, Wu L, Xu L, Longo N, McKee K, O’Dell S, Louder MK,Wycuff D, Feng Y, Nason M, Doria-Rose N, Connors M, Kwong PD, Roederer M, Wyatt RT, Nabel GJ, Mascola JR. (2010). Rational Design of Envelope Surface Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1. Science, 329, 856-861. (*Co-first authors). PMCID: PMC2965066.

Li, Y., Migueles, S., Welcher, B., Svehla, K., Phogat, A., Louder, M.K., Wu, X., Shaw, G.M., Connors, C., Wyatt, R*., and Mascola, J.R*. (2007). Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nature Medicine, 13, 1032-1034. PMCID: PMC2584972.